drugset / Trial / NCT03941548

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

NCT03941548

Phase 2 Completed 66 enrolled Concert Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.

Timeline

Start
2019-05-24
Primary completion
2020-04-10
Completion
2020-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-543 Unknown 12 mg
Subject CTP-543 Unknown 24 mg

Indications